Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s13365-017-0562-8 http://scihub22266oqcxt.onion/10.1007/s13365-017-0562-8 28831691!ä!28831691 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Neurovirol 2017 ; 23 (5): 786-788 Nephropedia Template TP {{tp|p=28831691|t=2017. Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy |pdf=|usr=}}{{28831691}} gab.com Text Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy JO: J Neurovirol http://www.kidney.de/pget.php?&tw=1&pmid=28831691 #FOAvip Parvovirus B19 (PB19) is a common, widespread, small, single-stranded DNA virus which has been linked with a broad spectrum of clinical illnesses, including a variety of neurological complications such as encephalitis, meningitis, myelitis, stroke, cerebellar ataxia, and neuropathy. The authors describe a case of PB19 infection associated with hemolytic anemia and cranial polyneuropathy involving the second and third cranial nerves in a 23-year-old immunocompetent woman. The diagnosis of acute PB19 infection was established with detection of positive DNA and anti-PB19 IgM antibodies in blood samples. Antiganglioside antibody studies were performed and serum anti-GD1b IgG was strongly positive. Further investigation was normal or negative, excluding other infectious or autoimmune disorders. The patient was initially treated with a 5-day course of intravenous immunoglobulin (IGIV). Because of incomplete neurological recovery, methylprednisolone was also administered 7 days after IGIV therapy initiation. Complete resolution of clinical symptoms was observed 3 months after disease onset at follow-up visit, despite the persistence of PB19 DNA and anti-PB19 IgM antibodies in serum 5 months after the initial presentation. Our report provides evidence that PB19 could affect both the central and peripheral nervous system, possibly by triggering an autoimmune mechanism that leads to autoantibody production. Twit Text FOAVip Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy ????J Neurovirol http://www.kidney.de/pget.php?&tw=1&pmid=28831691 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28831691 #FOAvip English Wikipedia <ref>{{Cite pmid|28831691}}</ref> Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy #MMPMID28831691 Sequeira J; Calado A; Dias M; Manita M J Neurovirol 2017[Oct]; 23 (5): 786-788 PMID28831691show ga Parvovirus B19 (PB19) is a common, widespread, small, single-stranded DNA virus which has been linked with a broad spectrum of clinical illnesses, including a variety of neurological complications such as encephalitis, meningitis, myelitis, stroke, cerebellar ataxia, and neuropathy. The authors describe a case of PB19 infection associated with hemolytic anemia and cranial polyneuropathy involving the second and third cranial nerves in a 23-year-old immunocompetent woman. The diagnosis of acute PB19 infection was established with detection of positive DNA and anti-PB19 IgM antibodies in blood samples. Antiganglioside antibody studies were performed and serum anti-GD1b IgG was strongly positive. Further investigation was normal or negative, excluding other infectious or autoimmune disorders. The patient was initially treated with a 5-day course of intravenous immunoglobulin (IGIV). Because of incomplete neurological recovery, methylprednisolone was also administered 7 days after IGIV therapy initiation. Complete resolution of clinical symptoms was observed 3 months after disease onset at follow-up visit, despite the persistence of PB19 DNA and anti-PB19 IgM antibodies in serum 5 months after the initial presentation. Our report provides evidence that PB19 could affect both the central and peripheral nervous system, possibly by triggering an autoimmune mechanism that leads to autoantibody production. |Anemia, Hemolytic/*virology[MESH] |Autoantibodies/immunology[MESH] |Autoantigens/immunology[MESH] |Erythema Infectiosum/*complications/immunology[MESH] |Female[MESH] |Gangliosides/immunology[MESH] |Humans[MESH] |Oculomotor Nerve Diseases/*virology[MESH] |Optic Nerve Diseases/*virology[MESH] |Polyneuropathies/virology[MESH]Parvovirus B19 infection associated with hemolytic anemia and cranial (epmc).pdf DeepDyve Pubget Overpricing